Ignite Creation Date:
2025-12-24 @ 7:37 PM
Ignite Modification Date:
2026-06-11 @ 12:37 PM
Study NCT ID:
NCT00225303
Status:
COMPLETED
Last Update Posted:
2011-05-19
First Post:
2005-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TMC125-C227: A Phase II Randomized, Active-Controlled, Open Label Trial to Investigate the Efficacy and Tolerability of TMC125 in HIV-1 Infected Subjects, Who Are PI-Naive and With Documented Genotypic Evidence of NNRTI Resistance From Previous NNRTI Use
Sponsor:
Tibotec Pharmaceuticals, Ireland
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | HIV Infection | View |